AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06090136
Drug: TPN171H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg TPN171H tablets，single dose,oral
Trial: NCT00483977
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: oral for 2 weeks.
Trial: NCT02902861
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: methotrexate 50 mg/ml in syringes for sub-cutaneous injection; Once weekly (every 7 days) s.c. administration of 17.5 mg MTX; If PASI50 is not reached after 8 weeks, the dosing will be increased to 22.5 mg
Trial: NCT02902861
Drug: Placebo ( for Methotrexate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl-Solution manufactured to mimic Methotrexate
Trial: NCT04178785
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients electively admitted for laparoscopic hysterectomy will be approached for requirement. After obtaining a written informed consent, patients will be randomly assigned either to the study group (Remifentanil group) or to the control group (Fentanyl group) in a 1:1 ratio.
Trial: NCT01932801
Drug: XR-NTX
RxNorm normalized name: Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03532204
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At investigator's discretion
Trial: NCT02353975
Drug: SHR3824
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR3824 tablet,10mg, fasting conditions and high fat, high calorie breakfast.
Trial: NCT04355169
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT00135551
Drug: thiazide diuretics
RxNorm normalized name: althiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benidipie+thiazide diuretics, titlation scheme
Trial: NCT01586572
Drug: mOPV1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent type 1 oral poliovirus vaccine (mOPV1) containing at least106 TCID50 of Sabin- strain poliovirus type 1.
Trial: NCT01586572
Drug: bOPV 1,3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The bivalent vaccine containing at least 106 CCID50 of Sabin poliovirus type 1 and 105•8 CCID50 of Sabin poliovirus type 3.
Trial: NCT01021891
Drug: Technosphere®/Insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02460419
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine 1250mg/m2 bid, oral, for 14 days, every 3 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
Trial: NCT03714880
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of study medication vs placebo
Trial: NCT03068585
Drug: Neovasculgen (Cambiogeneplasmid)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment
Trial: NCT03695367
Drug: HTX-011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTX-011 (bupivacaine/meloxicam), 300 mg/ 9 mg via instillation.
Trial: NCT03695367
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen, 600 mg.
Trial: NCT03695367
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen, 1 g.
Trial: NCT03695367
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative IV ketorolac.
Trial: NCT00559819
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (orange juice), same volume as alcohol
Trial: NCT04465916
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT04465916
Drug: Nucleotide analogue (Entecavir or Tenofovir Disoproxil)
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT01809743
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fractional flow reserve is measured by inducing hyperaemia using central adenosine infusion.
Trial: NCT03519711
Drug: PTC923
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTC923 will be administered per dose and schedule specified in arm description.
Trial: NCT01497561
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will be randomly allocated to two dose administrations out of four possible doses. Administrated subcutaneously (s.c., under the skin)
Trial: NCT04961684
Drug: Loceryl 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One application per week for 3 months
Trial: NCT01397968
Drug: YKP3089
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, dose to be titrated Tablet, dose to be titrated
Trial: NCT01397968
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule Placebo tablet
Trial: NCT00057720
Drug: doxorubicin HCl liposome injection
RxNorm normalized name: DOXORUBICIN HYDROCHLORIDE LIPOSOME
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01287741
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle.
Trial: NCT01287741
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle.
Trial: NCT02930018
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator: Placebo
Trial: NCT01518894
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral solution Q24 hours for 14 days
Trial: NCT02593331
Drug: BFKB8488A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive either a single escalated dose of BFKB8488A administered SC or a single dose of BFKB8488A administered IV on Day 1.
Trial: NCT03085940
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00381602
Drug: GHRP-1/AG 70 mg depot in ESRD
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01987453
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet(s) administered orally once daily
Trial: NCT03383406
Drug: Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every cycle(4weeks)~Subject will receive Ifosfamide 1.5 g/m2 over 2 hours for Day1\~Day5 by Intravenous infusion, Etoposide 150 mg/m2 over 3 hours on Day1\~Day3 by Intravenous infusion, Cytarabine 100 mg/m2 over 1 hour on Day1\~Day3 by Intravenous infusion.
Trial: NCT00198107
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants assigned to placebo will take a placebo pill for the initial 8 weeks of treatment.
Trial: NCT03626337
Drug: Thiamine 100 MG/ML
RxNorm normalized name: thiamine 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg thiamine provided as intramuscular injection
Trial: NCT00934661
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single epidural injection will be a placebo consisting of 0.4 ml of saline followed by 1 ml saline flush
Trial: NCT00602082
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04575935
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive standard of care chemotherapy
Trial: NCT02232906
Drug: intravenous ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose (FCM) dose of 1,000 mg iron, followed by a 6-month ESA/FCM maintenance regimen (target: Hemoglobin 120 g/L, transferrin saturation \>20%)
Trial: NCT00110747
Drug: S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-Caine Peel comprising a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine was applied topically. A thin layer of the peel (approximately 1 mm in thickness) was applied and remained on the treatment area for 30 minutes (±2 minutes).
Trial: NCT00110747
Drug: Placebo Peel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peel was applied topically. A thin layer of the peel (approximately 1 mm in thickness) was applied and remained on the treatment area for 30 minutes (±2 minutes).
Trial: NCT00364104
Drug: Quadruple sequential Helicobacter pylori eradication + iron sulfate
RxNorm normalized name: Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 10-day course of Hp infection sequential eradication therapy plus 6-weeks of iron supplementation
Trial: NCT00364104
Drug: Quadruple sequential Helicobacter pylori eradication therapy
RxNorm normalized name: Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 10-day course of Hp infection sequential eradication therapy only plus 6-weeks of matching placebo of iron supplementation
Trial: NCT00364104
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo only (10-days of matching placebo of Hp eradication therapy and 6-weeks of matching iron supplementation).
Trial: NCT02132429
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo containing no active drug
Trial: NCT02644421
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04188561
Drug: Intra articular injection Group
RxNorm normalized name: meningococcal group B vaccine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients included in the study had been received 2 ml high molecular weight (1.476 x 106 average Daltons) hyaluronic acid with concentration of 22mg/ml (OPTIVISC UK hyaluronic acid for intra articular injection). Platelet rich plasma is arranged by withdrawing 10 ml of patient's personal venous blood, anticoagulant is added, and centrifuged by duo-spin method, at the rate of 3500 rpm for five minutes then injected twice with 2 weeks interval. 3 distinct layers are produced by the end of the centrifugation: plasma, buffy coat (platelet) and RBCs, about 3 - 3.5 ml of PRP is produced~at the end with platelet concentration of 1.4 - 1.6 million/μl on average.
Trial: NCT01628666
Drug: Incremental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Cefazolin and Vancomycin preoperatively, bacitracin wash and cefalexin post operative.
Trial: NCT00510822
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT01432730
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets, BID
Trial: NCT02822118
Drug: Chang'an I Recipe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group were administered the Chang'an I Recipe, 150ml/bag, 3 times/day for 8 weeks.
Trial: NCT02822118
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group were administered the placebo, 150ml/bag, times/day for 8 weeks.
Trial: NCT03108664
Drug: SYL1001 ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop in the affected eye
Trial: NCT03108664
Drug: Vehicle opthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop in the affected eye
Trial: NCT02883400
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: spironolactone 25 mg up to 50 mg
Trial: NCT03195270
Drug: [18F]FDG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mCi of \[18F\]FDG via the antecubital vein in a bolus injection
Trial: NCT00187005
Drug: L-asparaginase, Methotrexate, Idarubicin, Etoposide, Cyclophosphamide, Cytarabine, Mercaptopurine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Detailed Description section for details of treatment interventions.
Trial: NCT02032394
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 ml .9%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
Trial: NCT03315780
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03353025
Drug: dopamine agonist treatment
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimum effective dose of dopamine agonist，bromocriptine，treat prolactinona
Trial: NCT03881852
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosed orally, twice daily for up to 3 weeks
Trial: NCT00538018
Drug: Telithromycin
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01794767
Drug: 0,9% NaCl flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline solution
Trial: NCT01794767
Drug: Heparin 50U/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin solution
Trial: NCT02297594
Drug: AK0529
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK0529 capsule for oral administration
Trial: NCT02297594
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar placebo capsule for oral administration
Trial: NCT02477072
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin doses will be administered according to the assigned group.
Trial: NCT03143712
Drug: GLPG1690
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of GLPG1690 in three different treatment conditions (treatment A through C)
Trial: NCT01361308
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo in a 1:1 ratio, administered once daily at bedtime beginning on Day 1 and continuing up to Day 84
Trial: NCT01710007
Drug: 1PC002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedtime or at regular time-interval is recommended.
Trial: NCT00707889
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 IV bolus on Day 1 of each 14-day cycle; followed by 2400 mg/m2 IV infusion 46-48 hours
Trial: NCT00003582
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03387085
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Trial: NCT03387085
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Trial: NCT03387085
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
Trial: NCT00482976
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02965027
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01759446
Drug: Placebo taken first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Snorted in both nostrils within 5 minutes; 48 hours washout between doses
Trial: NCT01759446
Drug: Generic H/A taken first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Snorted in both nostrils within 5 minutes; 48 hours washout between doses
Trial: NCT01759446
Drug: Vycavert taken first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Snorted in both nostrils within 5 minutes; 48 hours washout between doses
Trial: NCT01759446
Drug: Generic H/A plus i taken first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Snorted in both nostrils within 5 minutes; 48 hours washout between doses
Trial: NCT01759446
Drug: Generic H/A plus p taken first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Snorted in both nostrils within 5 minutes; 48 hours washout between doses
Trial: NCT01483365
Drug: Vaginal tablet Endometrin twice a day
RxNorm normalized name: Endometrin Vaginal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometrin 100 mg twice a day
Trial: NCT02734459
Drug: cataract surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the patient will be dosed with the study drug into the V pocket is formed between the eye ball and the lower eyelid during cataract surgery.
Trial: NCT00354432
Drug: Placebo Pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive oral placebo pill.
Trial: NCT01818011
Drug: GSK1322322 Initial fit for purpose tablets
RxNorm normalized name: Corona Multi-Purpose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beige, capsule shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1500 mg (3 x 500 mg) for single dose oral administration in Part A
Trial: NCT01818011
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light beige, oval-shaped, film-coated tablet for repeat dose oral administration (BID for 6 days) in Part C
Trial: NCT01818011
Drug: GSK1322322 for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White to slightly colored lyophilized powder cake in clear glass vials with unit dose strength of 400 mg/vial and dose levels of 600 mg (1.5 x 400 mg/vial), 900 mg (2.25x400mg/vial), 1200 mg (3x400mg/vial and 1200 mg (3 x 400 mg) for IV administration either as single dose in Part B or as a repeat dose (BID for 4 days) in Part C
Trial: NCT01818011
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A clear and colorless 0.9% Sodium Chloride solution for intravenous administration twice daily for 4 days in Part C
Trial: NCT03218657
Drug: Androgens
RxNorm normalized name: ANDROGENS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgens take orally 80mg qd
Trial: NCT02087865
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00487656
Drug: ART-123
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6mg/ml ampule solution for injection @ .01mg/kg
Trial: NCT00487656
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/ml ampule solution for injection at .01mg/kg
Trial: NCT00240396
Drug: Narcotics alone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03419923
Drug: two stage regional citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow(3/4 x 1.2 x blood flow)ml/h,and at the venous bubble trap at a rate according to the blood flow(1/4 x 1.2 x blood flow)ml/h.
Trial: NCT03419923
Drug: one stage regional citrate
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow( 1.2 x blood flow)ml/h.
Trial: NCT04646044
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care Treatment for COVID-19 Infection
Trial: NCT00882804
Drug: placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 % albumin will be administered through a large-caliber peripheral vein at a dose at a rate of 60 mL/hour.
Trial: NCT01001195
Drug: AGN-210669 ophthalmic solution, 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop of AGN-210669 ophthalmic solution, 0.1% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
Trial: NCT01001195
Drug: AGN-210669 ophthalmic solution, 0.075%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop of AGN-210669 ophthalmic solution, 0.075% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
Trial: NCT01001195
Drug: AGN-210669 ophthalmic solution, 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop of AGN-210669 ophthalmic solution, 0.05% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
Trial: NCT00787358
Drug: ZT-031
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 ul subcutaneous injection per day
Trial: NCT05109143
Drug: Indomethacin suppository
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg Indomethacin Suppository administered at the time of Induction